THE HUMAN GENOME PROJECT
In 2001, the Human Genome Project completed its first draft. The endeavor cost approximately $2.7 billion over 13 years, involving 20 institutions across 6 countries. This massive undertaking laid the foundation for modern genomics but was prohibitively expensive for clinical use.
454 SEQUENCING BREAKTHROUGH
454 Life Sciences introduced the first commercial next-generation sequencer, reducing costs to approximately $500,000 per genome. This represented a 200x improvement over Sanger sequencing, though still far from clinical viability.
ILLUMINA DOMINANCE
Illumina's HiSeq platforms drove costs below $10,000 per genome. The $1,000 genome threshold seemed within reach. Clinical applications began emerging: cancer genomics, rare disease diagnosis, and pharmacogenomics entered the conversation.
NANOPORE REVOLUTION
Oxford Nanopore's portable sequencers brought real-time, long-read sequencing to field applications. While per-genome costs remained higher than Illumina for bulk sequencing, the technology enabled rapid pathogen detection and environmental monitoring anywhere.
THE $600 GENOME ERA
Today, whole-genome sequencing costs approximately $600—less than many routine medical tests. The challenge has shifted from cost to interpretation: turning raw genomic data into actionable clinical insights requires sophisticated bioinformatics and large reference databases.